Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Indication

Breast Carcinoma

63 clinical trials

92 products

28 drugs

Clinical trial
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-11-01
Product
XL092
Product
Atezolizumab
Product
Avelumab
Product
NKT3447
Product
XL102
Clinical trial
A Dose Escalation and Expansion Study of the Safety and Pharmacokinetics of XL102 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Orally Available CDK2 Inhibitor NKT3447 in Adults With Advanced/Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2025-03-01
Product
Fulvestrant
Product
Abiraterone
Product
Prednisone
Clinical trial
A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy (OPERA-01)
Status: Recruiting, Estimated PCD: 2026-06-30
Product
Letrozole
Product
Palazestrant
Product
Anastrozole
Product
Exemestane
Clinical trial
A Phase I Dose Escalation and Dose Expansion and Phase II Monotherapy Open-label, First-in-Human, Multicenter Study of OP-1250 in Adult Subjects With Advanced and/or Metastatic Hormone Receptor (HR)-Positive, HER2-negative Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Product
OP-1250
Clinical trial
SHARON: Study of Metastatic Cancers in Patients With a Defect in a Homologous Recombination Gene Using Autologous Stems Cells and Potentiated Redox Cycling to Overcome Drug Resistance to Nitrogen Mustard Derivatives
Status: Recruiting, Estimated PCD: 2025-12-01
Product
Melphalan
Product
Fruquintinib
Product
BCNU
Product
NUV-422
Clinical trial
Phase 1/2 Dose Escalation, Safety, Pharmacokinetics, and Efficacy Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
Status: Terminated, Estimated PCD: 2022-08-31
Clinical trial
A Multi-Center, Open-Label, Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anticancer Activity of Fruquintinib in Patients With Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2022-12-13
Product
Vitamin B12
Product
Vitamin C
Product
Ethanol
Clinical trial
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: Adaptive Clinical Treatment (ACT)
Status: Withdrawn, Estimated PCD: 2026-05-31
Drug
Atezolizumab
Drug
UTD1
Clinical trial
Phase II Trial to Evaluate the Efficacy of the FASN Inhibitor, TVB-2640, in Combination With Trastuzumab Plus Paclitaxel or Endocrine Therapy in Patients With HER2+ Metastatic Breast Cancer Resistant to Trastuzumab-Based Therapy
Status: Active (not recruiting), Estimated PCD: 2024-07-30
Product
Denifanstat
Clinical trial
Phase Ib Study of BYL719 (Alpelisib) in Combination With Androgen Receptor Inhibitor (Enzalutamide) in Patients With Androgen Receptor (AR)-Positive and PTEN Positive Metastatic Breast Cancer
Status: Completed, Estimated PCD: 2023-12-31
Drug
Alpelisib
Product
Enzalutamide
Clinical trial
Phase 1b/2 Study of Naxitamab (Danyelza), Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells in Advanced GD2-expressing Breast Cancers (DiG NKs)
Status: Recruiting, Estimated PCD: 2024-12-31
Drug
Gemcitabine
Drug
Naxitamab
Product
Universal Donor Expanded TGF-beta-imprinted NK Cells
Drug
Tiragolumab
Drug
Trastuzumab
Clinical trial
A Phase II Trial to Evaluate Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
Status: Not yet recruiting, Estimated PCD: 2025-03-01
Product
Abemaciclib
Product
Fluorine F 18 Fluoro Furanyl Norprogesterone
Product
Gonadotropin-releasing Hormone Analog
Drug
Tamoxifen
Product
Estradiol
Clinical trial
A Phase IIA Trial Assessing the Tolerability of Abemaciclib in Combination With Endocrine Therapy in Patients Age 70 and Older With Hormone Receptor Positive Metastatic Breast Cancer Who Have Progressed on or After Prior CDK 4/6 Inhibition
Status: Recruiting, Estimated PCD: 2024-08-21
Drug
AN0025
Product
Cobimetinib
Product
Vismodegib
Drug
Entrectinib
Product
Eribulin
Product
Hyaluronidase-zzxf/Pertuzumab/Trastuzumab
Clinical trial
PNV21-001: A Phase I Study of a Personalized Multi-Peptide Neo-Antigen Vaccine in Breast Cancer and PD1/PD-L1 Inhibitor-Refractory Melanoma
Status: Recruiting, Estimated PCD: 2024-11-01
Product
Neoantigen Peptide Vaccine
Clinical trial
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
Status: Recruiting, Estimated PCD: 2026-09-01
Product
Nivolumab
Product
Poly ICLC
Clinical trial
A Phase 1b Study of Neratinib, Pertuzumab, and Trastuzumab With Taxol (3HT) in Metastatic and Locally Advanced Breast Cancer, and Phase II Study of 3HT Followed by AC in HER2 + Primary IBC, and Neratinib With Taxol (NT) Followed by AC in HR+ /HER2- Primary IBC
Status: Active (not recruiting), Estimated PCD: 2026-01-01
Drug
cyclophosphamide
Drug
R-CHOP
Product
Neratinib
Product
Cabozantinib
Product
Pertuzumab
Clinical trial
Serial [F-18] Fluoroestradiol (FES) PET Imaging to Evaluate Endocrine-targeted Therapy
Status: Active (not recruiting), Estimated PCD: 2021-10-01
Product
F-18 16 Alpha-Fluoroestradiol
Product
Fludeoxyglucose F-18
Drug
Abraxane
Drug
FOLFOXIRI
Product
Niraparib
Clinical trial
Olaparib Plus Low-Dose Alpelisib for Breast Cancer: A ComboMATCH Treatment Trial
Status: Withdrawn, Estimated PCD: 2025-04-30
Drug
Alpelisib
Product
Olaparib
Product
Palbociclib
Clinical trial
Phase I Clinical Trial Assessing the Combination of Chemokine Modulation With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
Status: Completed, Estimated PCD: 2022-05-24
Drug
Celecoxib
Product
Cyclophosphamide
Product
Doxorubicin
Product
Paclitaxel
Product
Recombinant Interferon Alfa-2b
Drug
Rintatolimod
Clinical trial
Phase II Open-label Study of ARX788 (Anti-HER2 Antibody Drug Conjugate) for Patients With HER2-low Locally Advanced Unresectable / Metastatic Breast Cancer
Status: Not yet recruiting, Estimated PCD: 2027-09-30
Drug
ARX788
Clinical trial
A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Talazoparib
Clinical trial
A Phase 1B Trial Evaluating the Safety of Ribociclib, Tucatinib, and Trastuzumab in Patients With Metastatic, HER2+ Breast Cancer and a Multicenter, Randomized, Open-Label, Phase 2 Study of Preoperative Treatment With Ribociclib,Ttrastuzumab, Tucatinib, and Fulvestrant Versus Docetaxel, Carboplatin,Ttrastuzumab, and Pertuzumab in HR+/HER2+ Breast Cancer and Ribociclib, Trastuzumab, and Tucatinib Versus Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab in Patients With HR-/HER2+ Breast Cancer
Status: Recruiting, Estimated PCD: 2025-04-01
Product
Carboplatin
Drug
Docetaxel
Product
Ribociclib
Drug
Tucatinib
Product
Trastuzumab Emtansine
Clinical trial
ETHAN: A Phase II Study Comparing Different Endocrine THerapies for mAle Breast caNcer
Status: Recruiting, Estimated PCD: 2026-04-01
Product
Degarelix
Product
Vemurafenib
Product
Vinorelbine
Clinical trial
A Randomized Window of Opportunity Study of Preoperative Letrozole and Simvastatin Versus Letrozole Alone in Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer
Status: Recruiting, Estimated PCD: 2025-04-15
Product
Simvastatin
Clinical trial
IRENE Study: Phase 2 Study of INCMGA00012 and the Oncolytic Virus Pelareorep in Metastatic Triple Negative Breast Cancer
Status: Recruiting, Estimated PCD: 2024-06-30
Product
Pelareorep
Product
Retifanlimab
Clinical trial
A Phase 2 Pilot Window of Opportunity Study Turkey Tail Mushrooms (TTM) (Trametes Versicolor) in Post-Menopausal Women With HER2 (-) ER (+) Breast Cancer Planning to Undergo Surgical Therapy
Status: Not yet recruiting, Estimated PCD: 2026-12-30
Product
Coriolus Versicolor Extract
Clinical trial
A Phase II, Single Arm, Non-randomized Study of Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer
Status: Recruiting, Estimated PCD: 2024-05-01
Product
Aromatase inhibitor
Clinical trial
Effect of Huaier Granule on Postoperative Adjuvant Treatment for High-risk Early-stage Triple-negative Invasive Ductal Carcinoma: a Prospective, Multicenter, Randomized, Controlled, Open-label Study
Status: Recruiting, Estimated PCD: 2027-12-31
Product
Huaier Granule
Clinical trial
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2020-05-05
Product
Entinostat
Product
Alectinib
Drug
LHRH agonist
Product
Goserelin
Clinical trial
Overcoming PARP Inhibitor Resistance in BRCA Germline Mutation Positive Advanced Breast Cancer
Status: Recruiting, Estimated PCD: 2025-03-31
Product
Cediranib
Drug
Ceralasertib
Clinical trial
Efficacy and Tolerability of Nanoparticle Albumin Bound Paclitaxel (Abraxane) in Patients 65 and Older With Locally Advanced or Metastatic Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2017-05-17
Clinical trial
A Phase II Single Arm Trial Evaluating the Safety and Efficacy of Anhydrous Enol-Oxaloacetate on Improving Cognitive Complaints in Breast Cancer Survivors
Status: Recruiting, Estimated PCD: 2024-11-01
Product
Anhydrous Enol-oxaloacetate
Clinical trial
A Phase 1, Randomized, Double Blinded, Placebo Controlled Study of the Safety and Efficacy of a Caffeine-based Antifibrosis Cream in Patients With Breast Cancer Undergoing Radiation Therapy
Status: Active (not recruiting), Estimated PCD: 2024-04-01
Product
Caffeine anhydrous
Clinical trial
A Phase II Open-Label, Randomized Study of PARP Inhibition (Olaparib) Either Alone or in Combination With Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2024-08-31
Clinical trial
BLESSED: Expanded Access for DeltaRex-G for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast
Status:
Drug
DeltaRex-G
Clinical trial
Phase 2 Trial of Fulvestrant and Binimetinib in Patients With Hormone Receptor-Positive Metastatic Breast Cancer With Inactivating or Inferred Inactivating NF1 Alterations: A ComboMATCH Treatment Trial
Status: Recruiting, Estimated PCD: 2026-11-01
Product
Binimetinib
Clinical trial
Molecular Analysis for Combination Therapy Choice (ComboMATCH)
Status: Recruiting, Estimated PCD: 2030-07-01
Clinical trial
A Phase I Study of AZD8186 in Combination With Docetaxel in Patients With PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel
Status: Active (not recruiting), Estimated PCD: 2022-07-25
Product
AZD8186
Drug
fluorouracil
Product
Ipatasertib
Clinical trial
Pharmacodynamic Study of Estrogen Suppression Threshold-Directed Therapy (ESTDT) of Anastrozole as Adjuvant Therapy for Early Stage Breast Cancer
Status: Completed, Estimated PCD: 2022-12-12
Clinical trial
OASIS: Phase II Trial of OrAl SM-88 in Patients With Metastatic Hormone Receptor-posItive HER2-negative (HR+/HER2-) breaSt Cancer
Status: Terminated, Estimated PCD: 2023-02-10
Product
SM-88
Drug
mFOLFOX6
Product
Nilotinib
Clinical trial
A Randomized Clinical Trial Comparing ctDNA-Directed Therapy Change With Standard of Care in Patients With Metastatic Triple Negative Breast Cancer
Status: , Estimated PCD: 2027-10-01
Product
Sacituzumab Govitecan
Product
Panitumumab
Product
Selumetinib
Product
Sotorasib
Clinical trial
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Completed, Estimated PCD: 2014-04-21
Clinical trial
PRE-Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis: A Phase I/Ib Platform Trial
Status: Recruiting, Estimated PCD: 2026-12-30
Product
ALX148
Product
Fam-Trastuzumab Deruxtecan
Clinical trial
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2024-04-30
Clinical trial
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2023-02-01
Drug
Tucidinostat
Product
Zanidatamab
Product
Systemic Chemotherapy
Product
Tamoxifen Citrate
Clinical trial
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB-43395, Alone or as Part of Combination Therapies in Patients With Metastatic HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-05-01
Product
BGB-43395
Clinical trial
Phase 1/1B Study of DS-8201a in Combination With ATR Inhibition (AZD6738) in Advanced Solid Tumors With HER2 Expression (DASH Trial)
Status: Recruiting, Estimated PCD: 2026-03-31
Product
Trastuzumab Deruxtecan
Clinical trial
A Phase 1/2a, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
Status: Recruiting, Estimated PCD: 2025-04-01
Product
IMT-009
Clinical trial
A Phase II Open Label Trial of Neo-Adjuvant Abemaciclib With Fulvestrant in Patients Who Develop Localized Recurrence While on Adjuvant Endocrine Therapy With Molecular Evidence of Endocrine Resistance
Status: Terminated, Estimated PCD: 2022-02-16
Clinical trial
Prophylactic Lymphovenous Bypass Procedure Following Axillary Lymphadenectomy: A Prospective Observational Study
Status: Recruiting, Estimated PCD: 2025-12-31
Product
Indocyanine Green
Clinical trial
Phase II Trial of Radium-223 Dichloride in Combination With Paclitaxel in Patients With Bone Metastatic Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2025-06-30
Clinical trial
A Phase II Randomized Study of Ixabepilone vs. Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2/Neu-Negative Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Product
Ixabepilone
Clinical trial
Monitoring Neoadjuvant Chemotherapy of Breast Cancer Using 3D Subharmonic Aided Pressure Estimation
Status: Recruiting, Estimated PCD: 2026-05-31
Product
Perflutren Lipid Microspheres
Clinical trial
Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer
Status: Recruiting, Estimated PCD: 2026-05-31
Clinical trial
A Phase II, Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of Trastuzumab Deruxtecan (DS-8201a) With or Without Anastrozole for HER2 Low Hormone Receptor Positive (HR+) Breast Cancer in the Neoadjuvant Setting
Status: Recruiting, Estimated PCD: 2025-09-30
Drug
doxorubicin
Clinical trial
The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib
Status: Recruiting, Estimated PCD: 2028-01-01
Product
Placebo
Clinical trial
A Phase 1b Study of Berzosertib in Combination With Radiation Therapy to Overcome Therapeutic Resistance in Chemotherapy Resistant Triple Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2024-11-20
Product
Berzosertib
Clinical trial
DATO-BASE: A Phase 2 Trial of DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
Status: Recruiting, Estimated PCD: 2028-01-01
Product
Datopotamab Deruxtecan
Clinical trial
ISPY-P1.01: Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer: A Phase I/Ib Trial
Status: Withdrawn, Estimated PCD: 2021-11-17
Product
Vic-trastuzumab duocarmazine
Clinical trial
Phase II Trial of Single Agent ABT-888 With Post-Progression Therapy of ABT-888 in Combination With Carboplatin in Patients With Stage IV BRCA-Associated Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2025-06-30
Product
Veliparib
Clinical trial
A Randomized Phase I/II Trial of Fulvestrant and Abemaciclib in Combination With Copanlisib (FAC) Versus Fulvestrant and Abemaciclib Alone (FA) for Endocrine-Resistant, Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer (FAC vs FA)
Status: Active (not recruiting), Estimated PCD: 2023-06-22
Product
Copanlisib
Clinical trial
Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer
Status: Not yet recruiting, Estimated PCD: 2026-09-01
Product
Axatilimab
Drug
olaparib